Abstract
Azacitidine is a novel agent for treating myelodysplastic syndromes (MDS). It has a relatively safe toxicity profile with very few reported skin toxicities. Patients with MDS were prone to get severe infections, especially via respiratory tract, urinary system, and bloodstream. However, necrotizing fasciitis (NF) is a relatively rare event in patients with MDS, and it is hard to diagnose early. Here, we report two MDS cases that developed NF in lower extremities while receiving azacitidine treatment. One of them survives after emergent fasciotomy along with the administration of broad-spectrum antibiotics and intravenous immunoglobulin.
Keywords:
azacitidine; myelodysplastic syndrome; necrotizing fasciitis.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / adverse effects*
-
Azacitidine / administration & dosage
-
Azacitidine / adverse effects*
-
Fasciitis, Necrotizing / drug therapy
-
Fasciitis, Necrotizing / etiology*
-
Fasciitis, Necrotizing / pathology
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / etiology*
-
Klebsiella Infections / pathology
-
Klebsiella pneumoniae / isolation & purification
-
Leg / microbiology
-
Leg / pathology
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
-
Myelodysplastic Syndromes / pathology
Substances
-
Anti-Bacterial Agents
-
Antimetabolites, Antineoplastic
-
Immunoglobulins, Intravenous
-
Azacitidine